Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00412958 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
A Phase 2 study of Vitrectomy, sponsored by ThromboGenics.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT00412958 is a Phase 2 study of Vitrectomy that has completed, run by ThromboGenics. The registered enrollment target is 125 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT00412958, a Phase 2 study of Vitrectomy, has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
A multicenter study to compare multiple doses of intravitreal microplasmin in patients undergoing surgical vitrectomy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ocriplasmin 25µg
- DRUG Ocriplasmin 75µg
- DRUG Ocriplasmin 125µg
Study Locations (20)
California
- VMR Institute - Huntington Beach
- Jules Stein Eye Institute/UCLA - Los Angeles
- Retinal Consultants of San Diego - Poway
- Retinal Consultants Medical Group - Sacramento
Florida
- National Ophtlamic Research Institute - Fort Meyers
- Center for Retina and Macular Disease - Winter Haven
New York
- Columbia University - Harkness Eye Institute - New York
- Retina Vitreous Surgeons of Central NY - New York
Texas
- Vitreoretinal Consultants - Houston
- Valley Retina Institute, P.A. - McAllen
Arizona
- Retina Centers, P.C. - Tucson
Illinois
- Rush University Med. Ctr - Chicago
Massachusetts
- Mailing add: New England Eye Center - Tufts - Boston
Michigan
- Associated Retinal Consultants, P.C. - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00412958
The ClinicalTrials.gov registry entry for NCT00412958 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ThromboGenics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vitrectomy appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00412958 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00412958 about?
NCT00412958 is a clinical study titled "A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)". A multicenter study to compare multiple doses of intravitreal microplasmin in patients undergoing surgical vitrectomy.
What is the current status of trial NCT00412958?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2006-12. Estimated completion is 2008-10.
What conditions does trial NCT00412958 study?
This clinical trial studies the following conditions: Vitrectomy.
What interventions are being tested in trial NCT00412958?
The interventions under investigation include: Placebo (DRUG), Ocriplasmin 25µg (DRUG), Ocriplasmin 75µg (DRUG), Ocriplasmin 125µg (DRUG).
Who is sponsoring clinical trial NCT00412958?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00412958 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vitrectomy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.